Treatment of Esophageal Varices with Bleeding in Non-Cirrhotic Portal Hypertension with Large Splenomegaly

Esophageal variceal bleeding arising in non-cirrhotic portal hypertension (NCPH) represents a clinically distinct presentation. Recognising the correct underlying context is essential, as management considerations differ from those applicable in cirrhotic portal hypertension.

Clinical Scenario

The patient has esophageal variceal bleeding in the setting of non-cirrhotic portal hypertension, with the characteristic triad of absent ascites, absent jaundice, and absent hepatic encephalopathy, alongside the presence of large splenomegaly. Together, these features are the key clinical clues that distinguish NCPH from cirrhotic portal hypertension.

Treatment Approach

Management involves a combination of vasoactive therapy and endoscopic intervention — the complete protocol specifies which agents are appropriate, the preferred endoscopic approach, and the specific guidance on antibiotics and coagulopathy correction in this non-cirrhotic context.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s12072-025-10894-4

Absence of ascites, jaundice, and hepatic encephalopathy, and presence of large splenomegaly are the clinical clues in differentiating NCPH from cirrhotic portal hypertension (CPHT).
First-line treatment options are essentially the same as in cirrhosis patients.
Vasoactive drugs, such as somatostatin, octreotide, or terlipressin have been used in the treatment of AVB while endoscopic therapy is being arranged.
At present, band ligation is preferred owing to lower complication rates.
Antibiotics are not recommended in AVB in NCPF, unless absolute neutrophil count is <1,000 mm⁻³.

View source ↗